Články a aktuality 2012 - 2018

Background and aim:Cancer biomarkers are important for cancer patient management. Most clinically used cancer biomarkers were discovered 30-50 years ago. No new biomarkers have entered the clinic recently, with the exception of molecular biomarkers that are mainly used for selection of therapy. We here propose new ideas for utilizing a plethora of cancer biomarkers which work for only for a small portion of patients (rare biomarkers).

Patients and methods: We will provide examples of 5-10% of patients with pancreatic cancer who have elevated circulating serum biomarkers that have not been described before. We will then propose a scheme for screening of thousands of candidate biomarkers, to select a few that work best for a small number of patients.

Results: We propose a method for identifying personalized cancer biomarkers. These biomarkers are circulating proteins or circulating tumor DNA. We will discuss the utility of circulating tumor DNA for various clinical applications, including patient management and early detection.

Conclusion: Personalized biomarkers can now be identified with high throughput techniques and utilized to optimize cancer patient treatment